Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
m (sensa categ) |
(→ATC) |
||
| Line 12: | Line 12: | ||
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure). | ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure). | ||
==ATC== | ==ATC== | ||
http://www.whocc.no/atc_ddd_index/?code=C10AB02 | |||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | |||
|colspan=2| <center> | |||
: [[wikipedia:bezafibrate|bezafibrate]] | |||
<ref>http://www.whocc.no/atc_ddd_index/?code=C10AB02</ref></center> | |||
|} | |||
<references/> | <references/> | ||
Revision as of 00:53, 5 November 2015
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases This fibrate reduce triglyceride and riseHDL-cholesterol[1][2]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure).
ATC
- ↑ How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?
- ↑ Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.
- ↑ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
- ↑ Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
- ↑ http://www.whocc.no/atc_ddd_index/?code=C10AB02